NIAID Preclinical Development Support - Development of clade C Vaccine

点击翻译按钮获取中文摘要

This contract will provide NIAID with a broad and flexible range of nontraditional, proactive and developmentally-oriented capabilities to provide preclinical development support for promising products when such products emerge from investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. Activities include but are not limited to small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing. The primary aim is for the development of a Ad4 1086 HIV Clade C envelope vaccine.